Overcoming platinum resistance in ovarian carcinoma. - Wikidata - awgldk - TriplyDB

Overcoming platinum resistance in ovarian carcinoma.

Overcoming platinum resistance in ovarian carcinoma.

http://www.wikidata.org/entity/Q34233273

about

Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Targeting SRC in mucinous ovarian carcinoma.Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.Therapeutic strategies in epithelial ovarian cancer.Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.Overcoming platinum resistance through the use of a copper-lowering agent Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature.Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.2-Deoxy-d-Glucose Sensitizes Human Ovarian Cancer Cells to Cisplatin by Increasing ER Stress and Decreasing ATP Stores in Acidic Vesicles.BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.Myriocin induces apoptotic lung cancer cell death via activation of DR4 pathway.Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer.Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer.Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells.Verrucarin J inhibits ovarian cancer and targets cancer stem cells.Repositioning of proton pump inhibitors in cancer therapy.Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report.Nivolumab use for gene mutation carriers with recurrent epithelial ovarian cancer: A case series Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies

P2860

Q28535582-A75D1D30-2CFE-4D3C-A3FC-9B77F0923300 Q28543359-CAD65E6A-5B1F-40D8-B5F5-635BF9BBE5C2 Q33578254-DC3056AD-FDAE-4566-B364-C7D8025D9DBD Q33638051-7DAD72A7-DB41-4548-9A44-F28122F46158 Q34219967-7D856B6B-5C6A-43E4-8DC1-9B1C8DD7336F Q34241202-4545F80D-C3EF-41DE-8A33-248B9CAC97B1 Q34292101-1BE08DE9-929F-4107-87C8-4718E785D553 Q34347621-403CF55E-3245-47E8-A83C-2FF7976C4437 Q35109273-C21520D0-34B7-44BF-9173-D0C17E48A8C4 Q35653739-4462A529-612E-4ED9-90B6-7B13D43C68E0 Q35845484-EEEC80E7-4703-474C-B0D9-40643DFCFF94 Q36109004-F02504D6-B258-4C08-A638-6B8539A457C8 Q36249363-BCF3DA57-F93C-4934-B9D0-C08B6F2E1F24 Q36544294-80B5EDC8-8F69-431A-87F2-812DFACDCC5B Q36545468-DC3DE8A3-4669-455C-A6AC-BE8481FDBE94 Q36886892-3C1DE5C6-FD05-4A8C-A65D-94B84968342B Q36918550-83ED55B4-0456-46A8-9F17-DC88915F44F4 Q37046805-74BB9080-9AFE-40F1-8625-8FD591A0ECF4 Q37113732-9B413131-7B00-4C6B-97CC-E31CFA317B52 Q37225627-19182EA4-5875-4435-AE4C-4D9CD5714832 Q37276254-A83E614E-7387-445F-AD26-50CB1733D196 Q37295618-057C57D5-C420-4F74-BFB3-1BD01214A9EB Q37530604-803EBE81-85E5-41A9-8764-BF1B1D690F4C Q37611723-DEF83184-8700-4852-A320-65FF62D28D98 Q37625369-3D22764E-02CC-4719-8683-6A45A3ECF379 Q38813996-10438241-3F0A-4C2E-8471-C668D767344D Q38846410-D4F0289B-CAD4-4A00-AF9B-6DDABF28F86E Q38965047-A1BF494E-1031-4408-B6A2-74AD7464801D Q38966925-243B4EC9-BB69-4C86-ADB0-C97E16F5332C Q39036953-044E8E3D-93EB-4554-B7FB-CEEA5E36C3BF Q40571932-4D3C3F9F-C3B8-4490-B6EB-4B278EC3DE78 Q42425714-3B1887F8-1071-4818-B401-F768E384AEA9 Q42708068-6F12808E-F9A2-46F4-A93A-9F3C38550522 Q46070440-A3A6828B-E6E3-42F0-8780-43653E703302 Q46250945-EE15867E-17EE-41D3-BC98-B1DF48E6A26C Q48142620-150BF15F-36FE-48A3-AF48-2B886826C569 Q48617362-9665C689-28CB-4871-B482-AAB8A293B897 Q55436471-91D94E25-E425-4CE4-954B-C48B4F34E7B5 Q57210400-3B3458E4-E264-443E-8673-0F7A58E72820 Q58790039-31BECAAF-25E3-4B8C-88BF-6EA33FA585E0

P2860

Overcoming platinum resistance in ovarian carcinoma.

http://www.wikidata.org/entity/Q34233273

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Overcoming platinum resistance in ovarian carcinoma.

@ast

Overcoming platinum resistance in ovarian carcinoma.

@en

Overcoming platinum resistance in ovarian carcinoma.

@nl

type

label

Overcoming platinum resistance in ovarian carcinoma.

@ast

Overcoming platinum resistance in ovarian carcinoma.

@en

Overcoming platinum resistance in ovarian carcinoma.

@nl

prefLabel

Overcoming platinum resistance in ovarian carcinoma.

@ast

Overcoming platinum resistance in ovarian carcinoma.

@en

Overcoming platinum resistance in ovarian carcinoma.

@nl

P1433

Q34233273-3B7733E3-609F-443B-8B2B-A84E35C856B0

P1476

Q34233273-6307DC60-33D8-4771-9387-734DD5D4827B

P2093

Q34233273-2F030275-1BB9-4241-B33C-D7AFD97A60AA

Q34233273-3B6F7DFB-9C60-405B-82D2-FA94A8A447D5

Q34233273-56D8C17A-B1E5-4430-A329-B356DF09047D

Q34233273-FCAE4058-E4F6-462D-8608-C17C1D5465D6

P2860

Q34233273-00BEBD9C-B1A4-4111-AC23-88585B793D80

Q34233273-03CD2596-C94C-425F-A711-FF35CFD66C63

Q34233273-043464EF-25E8-44E3-9F41-972C5619BBD6

Q34233273-0697679A-47AC-4D18-B0AE-CC8988429EFC

Q34233273-06B74B85-094C-4522-9DAA-8E652A7A44B3

Q34233273-0FE30722-FF56-4307-B6FE-7F6B895A0D70

Q34233273-10A606A8-3152-4EA4-9912-1C5E7630AFAA

Q34233273-1BB694C5-919C-40E6-AD12-D8D87C49B677

Q34233273-1D368546-1236-46EC-99B4-368908DEE2B1

Q34233273-204C92C1-158E-43D2-95C5-12A5A5F9EEDA

P304

Q34233273-DCC7F1FA-8F89-42A8-BB3A-D0932833C4A0

P31

Q34233273-C9B2E76E-629C-4275-B9EA-5FC778FA2DA1

P356

Q34233273-04FBF0F4-6201-4079-B3C0-C7939093F023

P407

Q34233273-48C37782-86F7-4C4A-85ED-03499B335AE4

P433

Q34233273-D182250E-BC0A-4598-87A7-5FDA54043836

P478

Q34233273-206AEB44-A0AA-4210-B6EF-8FF56FAFFC21

P577

Q34233273-35283E3A-7183-4058-9F99-2B20135FC25E

P5875

Q34233273-6C642A44-9344-41B1-8F0A-EB45991D395C

P698

Q34233273-B4E9DE18-B96C-4DA0-9848-0CE151F7ED2D

P932

Q34233273-2B5B8D26-E787-446F-8C42-CF5555737E03

P356

13543784.2010.515585

P1433

Expert Opinion on Investigational Drugs

P1476

Overcoming platinum resistance in ovarian carcinoma.

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Koji Matsuo

http://www.w3.org/2001/XMLSchema#string

Lynda D Roman

http://www.w3.org/2001/XMLSchema#string

Yvonne G Lin

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2009

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.

Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.

P304

1339-1354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2010.515585

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46147137

http://www.w3.org/2001/XMLSchema#string

P698

20815774

http://www.w3.org/2001/XMLSchema#string

P932

2962713

http://www.w3.org/2001/XMLSchema#string